All lobbying filings

ABBOTT LABORATORIES

Lobbying for ABBOTT LABORATORIES

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $813,507.00 expenses · posted Jul 21, 2025

Official filing document

Bills named in this filing 5

HR 2300
To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other pu…
HR 9817
Toxic Free Food Act of 2024
S 2477
Equitable Community Access to Pharmacist Services Act
HR 1770
Equitable Community Access to Pharmacist Services Act
S 3387
Ensuring Safe and Toxic-Free Foods Act of 2023

Lobbying activity 6

Health Issues

S. 2477/H.R. 1770 Equitable Community Access to Pharmacist Services Act. Proposals related to medical device cybersecurity. Proposals related to the President's Emergency Plan for AIDS Relief (PEPFAR).

Medicare/Medicaid

Proposals related to Medicare coverage of continuous glucose monitors.

Trade (domestic/foreign)

Proposals related to tariffs on products imported into the United States. Proposals regarding US-China trade negotiations. Proposals related to U.S. global health programs and pandemic preparedness. Proposals to advance global virus surveillance. Proposals related to preserving critical medical supply chains.

Agriculture

H.R. 2300 To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes. Proposals related to access to infant formula.

Taxation/Internal Revenue Code

Proposals to reform domestic and international tax structures.

Food Industry (safety, labeling, etc.)

S. 3387 - Ensuring Safe and Toxic-Free Foods Act of 2023. H.R. 9817 Toxic Free Food Act of 2024.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.